---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-26-000003"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:51:47.937469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM

## Summary
- Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.
- 83% ORR and 22.1-month median PFS in r/r CLL with median 4 prior lines; 600 mg dose aligned with regulators.
- New tablet formulation for autoimmune; IND target 2026. Partnered IRAK4 (GS-6791, Phase 1) and STAT6 (IND-enabling).
- NX-1607 Phase 1a showed immune activation; confirmed partial response in MSS CRC across 82 patients.
- Pro forma cash $663.8M after $250M equity raise; added CCO and two new board members.

## SEC filing metadata
- accession: 0001549595-26-000003
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/0001549595-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/nrix-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-26-000003
- JSON: https://secwatch.observer/filing/0001549595-26-000003.json
- Plain text: https://secwatch.observer/filing/0001549595-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.